KS

Kuldeep Sharma

Active Director Director DIN 09617816
DIN 09617816 First appointment May 2022 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Kuldeep Sharma

Data last updated:

Kuldeep Sharma is a Director at Novatropics Pharma Private Limited (since 2022). The company operates in Chemicals.

DIN 09617816
Primary Designation Director
Industry Chemicals
First Appointment 24 May 2022
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Novatropics Pharma Private Limited U24230UR2022PTC014075
Director24 May 20222022Active

Board colleagues of Kuldeep Sharma

Directorship timeline

Open interactive timeline →
Novatropics Pharma Private Limited
Premium access

Shareholding and investment profile for Kuldeep Sharma

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kuldeep Sharma

Kuldeep Sharma currently holds 1 directorship: Novatropics Pharma Private Limited (Director, since 24 May 2022).

Kuldeep Sharma was first appointed on 24 May 2022 as Director at Novatropics Pharma Private Limited.

The current boards of Kuldeep Sharma's companies include Balvendra Singh Rawat (Novatropics Pharma Private Limited), Gaurav Kumar Yadav (Novatropics Pharma Private Limited), Kumar Pancham (Novatropics Pharma Private Limited), Pradeep Kumar (Novatropics Pharma Private Limited), Vikas Kumar (Novatropics Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available